Research In Brief
This article was originally published in The Gray Sheet
Executive SummaryXience v. Cypher "The unrestricted use of everolimus-eluting stents appears to be associated with improved clinical long-term outcome compared with sirolimus-eluting stents," Swiss researchers concluded from data presented Aug. 30 at the European Society of Cardiology annual conference in Stockholm. Using propensity score matching, the study retrospectively compared clinical outcomes from 1,342 pairs of patients treated with Abbott's Xience or Johnson & Johnson's Cypher. The composite endpoint of death, myocardial infarction and target vessel revascularization occurred in 14.9% of Xience patients and 18% of Cypher patients after up to three years of follow-up
You may also be interested in...
ConMed Corp. is company of two halves ̶ general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.
Drug pricing and access issues expose the pharmaceutical sector especially acutely to calls for companies to meet ethical and social goals, alongside commercial ones. Digital is up-ending pharma’s processes, its workplaces and its consumers. R&D productivity is spluttering. Amid this turmoil, CEOs highlight company culture – the way an organization behaves – as a crucial ingredient for success. But what is a “right” culture? Organizational culture is neither static nor singular. It is continuously influenced by acquisitions, markets, new technologies and new generations. And pharma’s history suggests that culture change cannot happen without sufficient people change.